Funding will advance small molecule therapeutics that tackle molecular damage and remove Advanced Glycation End Products.
Lento Bio, a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia patients, has announced it has raised $680,000 in funding during their recent oversubscribed seed round.
Ichor Life Sciences is the lead investor for the round, providing $400,000 in funding to Lento Bio.
Longevity.Technology: Lento Bio was launched in June of 2022 and is an Ichor Life Sciences portfolio company. The seed round will be used to conduct research and testing that will establish proof of concept for Lento Bio’s therapeutics and help optimise lead compounds in early-stage pre-clinical studies.
“We are extremely grateful for the support for our science that Ichor and other investors have shown us through this funding round”, said Dr Kris Barnes, PhD, Lento Bio CEO. “Since our launch, our focus has been to develop small-molecule therapeutics to treat presbyopia. This funding will help enable that goal by sustaining our preclinical activities through the next major steps in development.”
“We’re proud to provide funding for Lento Bio and support its work, which will advance the study of therapies to target advanced glycation end products – a molecular hallmark of aging”, said Dr Kelsey Moody, PhD, MBA, CEO, and Founder of Ichor Life Sciences.
“Lento Bio is making significant progress, and we look forward to our continued collaboration to further our knowledge and work treating degenerative disease.”
READ MORE: Revel Pharma – harnessing the power of therapeutic enzymes to tackle advanced glycation end products
Register or log in to access our new investment portal and catch up with the latest investment news and trends.